Evidence map›Paper›PMID 32169821›Full record

ArticleiScience2020

Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination during Lymphoid Development.

S Haihua Chu, Jonathan R Chabon, Chloe N Matovina, Janna C Minehart, Bo-Ruei Chen, Jian Zhang, Vipul Kumar, Yijun Xiong, Elsa Callen, Putzer J Hung and 7 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Cell discovery · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 1 country.

S Haihua ChuDepartment of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, 450 Brookline Avenue, Boston, MA 02215-5450, USA.
Jonathan R ChabonDepartment of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, 450 Brookline Avenue, Boston, MA 02215-5450, USA.
Chloe N MatovinaDepartment of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, 450 Brookline Avenue, Boston, MA 02215-5450, USA.
Janna C MinehartNew York University School of Medicine, New York, NY, USA.
Bo-Ruei ChenDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Jian ZhangCenter for Computational Biology, Beijing Institute of Basic Medical Sciences, Beijing, China; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Vipul KumarHoward Hughes Medical Institute, Department of Pediatrics, Department of Genetics, Harvard Medical School, Boston, MA, USA; Harvard-MIT MD-PhD Program, Harvard Medical School, Boston, MA, USA.
Yijun XiongDepartment of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, 450 Brookline Avenue, Boston, MA 02215-5450, USA.
Elsa CallenLaboratory of Genome Integrity, National Cancer Institute National Institutes of Health, Bethesda, MD, USA.
Putzer J HungDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Zhaohui FengDepartment of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, 450 Brookline Avenue, Boston, MA 02215-5450, USA.
Richard P KocheCancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
X Shirley LiuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jayanta ChaudhuriImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
Andre NussenzweigLaboratory of Genome Integrity, National Cancer Institute National Institutes of Health, Bethesda, MD, USA.
Barry P SleckmanDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Scott A ArmstrongDepartment of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, 450 Brookline Avenue, Boston, MA 02215-5450, USA. Electronic address: scott_armstrong@dfci.harvard.edu.
Dana-Farber Cancer Institute · USCornell University · USNational Institutes of Health · USBoston Children's Hospital · USHarvard University · USInstitute of Basic Medical Sciences of the Chinese Academy of Medical SciencesMemorial Sloan Kettering Cancer Center · USNew York University · USWashington University in St. Louis · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI MATTHEW S DAVIDS · 1996 to 2026
$52.5M
DNA RepairZIABC010283 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NUSSENZWEIG, ANDRE A. · 2009 to 2025
$27.0M
THE V(D)J RECOMBINATION REACTION AND ITS IMPACT ON LYMPHOCYTE DEVELOPMENTR01AI047829 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SLECKMAN, BARRY P · 2000 to 2021
$7.0M
ATM FUNCTION DURING V(D)J RECOMBINATIONR01AI074953 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SLECKMAN, BARRY P · 2009 to 2023
$5.9M
Targeting to Epigenetic Modications in ALLR01CA176745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ARMSTRONG, SCOTT A, QI, JUN · 2012 to 2022
$4.2M
Alternative End-Joining in DNA Repair and Chromosomal TranslocationsF30CA189740 · NCI · HARVARD MEDICAL SCHOOL · PI KUMAR, VIPUL · 2014 to 2018
$197k
NCI NIH HHS F30 CA189740NCI NIH HHS P01 CA066996NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA176745NIAID NIH HHS R01 AI047829NIAID NIH HHS R01 AI074953
6 · The paper itself

Abstract

Repair of DNA double-stranded breaks (DSBs) during lymphocyte development is essential for V(D)J recombination and forms the basis of immunoglobulin variable region diversity. Understanding of this process in lymphogenesis has historically been centered on the study of RAG1/2 recombinases and a set of classical non-homologous end-joining factors. Much less has been reported regarding the role of chromatin modifications on this process. Here, we show a role for the non-redundant histone H3 lysine methyltransferase, Setd2, and its modification of lysine-36 trimethylation (H3K36me3), in the processing and joining of DNA ends during V(D)J recombination. Loss leads to mis-repair of Rag-induced DNA DSBs, especially when combined with loss of Atm kinase activity. Furthermore, loss reduces immune repertoire and a severe block in lymphogenesis as well as causes post-mitotic neuronal apoptosis. Together, these studies are suggestive of an important role of Setd2/H3K36me3 in these two mammalian developmental processes that are influenced by double-stranded break repair.

Indexed as

Biological SciencesCell BiologyImmunologyMolecular Biology

Identifiers

PMID32169821
PMCPMC7066224
OpenAlexW3006794587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.